These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 19821999)

  • 1. BU-32: a novel proteasome inhibitor for breast cancer.
    Agyin JK; Santhamma B; Nair HB; Roy SS; Tekmal RR
    Breast Cancer Res; 2009; 11(5):R74. PubMed ID: 19821999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of a novel proteasome inhibitor BU-32 on multiple myeloma cells.
    Roy SS; Kirma NB; Santhamma B; Tekmal RR; Agyin JK
    Cancer Chemother Pharmacol; 2014 Jun; 73(6):1263-71. PubMed ID: 24728817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CIP2A is a target of bortezomib in human triple negative breast cancer cells.
    Tseng LM; Liu CY; Chang KC; Chu PY; Shiau CW; Chen KF
    Breast Cancer Res; 2012 Apr; 14(2):R68. PubMed ID: 22537901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A proteasome inhibitor, bortezomib, inhibits breast cancer growth and reduces osteolysis by downregulating metastatic genes.
    Jones MD; Liu JC; Barthel TK; Hussain S; Lovria E; Cheng D; Schoonmaker JA; Mulay S; Ayers DC; Bouxsein ML; Stein GS; Mukherjee S; Lian JB
    Clin Cancer Res; 2010 Oct; 16(20):4978-89. PubMed ID: 20843837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteasome inhibition represses ERalpha gene expression in ER+ cells: a new link between proteasome activity and estrogen signaling in breast cancer.
    Powers GL; Ellison-Zelski SJ; Casa AJ; Lee AV; Alarid ET
    Oncogene; 2010 Mar; 29(10):1509-18. PubMed ID: 19946334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines.
    Wang Y; Rishi AK; Puliyappadamba VT; Sharma S; Yang H; Tarca A; Dou QP; Lonardo F; Ruckdeschel JC; Pass HI; Wali A
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):455-66. PubMed ID: 19960346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity.
    Saha MN; Jiang H; Jayakar J; Reece D; Branch DR; Chang H
    Cancer Biol Ther; 2010 Jun; 9(11):936-44. PubMed ID: 20418664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential sensitivity of breast cancer and melanoma cells to proteasome inhibitor Velcade.
    Yerlikaya A; Erin N
    Int J Mol Med; 2008 Dec; 22(6):817-23. PubMed ID: 19020781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer.
    Shah SA; Potter MW; McDade TP; Ricciardi R; Perugini RA; Elliott PJ; Adams J; Callery MP
    J Cell Biochem; 2001 Apr 2-27; 82(1):110-22. PubMed ID: 11400168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
    Thaler S; Thiede G; Hengstler JG; Schad A; Schmidt M; Sleeman JP
    Int J Cancer; 2015 Aug; 137(3):686-97. PubMed ID: 25530422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2-positive breast cancer cells in a synergistic manner.
    Cardoso F; Durbecq V; Laes JF; Badran B; Lagneaux L; Bex F; Desmedt C; Willard-Gallo K; Ross JS; Burny A; Piccart M; Sotiriou C
    Mol Cancer Ther; 2006 Dec; 5(12):3042-51. PubMed ID: 17148762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of a novel proteasome inhibitor selective for cancer cells over non-transformed cells.
    Kazi A; Lawrence H; Guida WC; McLaughlin ML; Springett GM; Berndt N; Yip RM; Sebti SM
    Cell Cycle; 2009 Jun; 8(12):1940-51. PubMed ID: 19471122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model.
    Ishii Y; Pirkmaier A; Alvarez JV; Frank DA; Keselman I; Logothetis D; Mandeli J; O'Connell MJ; Waxman S; Germain D
    J Natl Cancer Inst; 2006 Sep; 98(17):1238-47. PubMed ID: 16954476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma.
    Altmann A; Markert A; Askoxylakis V; Schöning T; Jesenofsky R; Eisenhut M; Haberkorn U
    J Nucl Med; 2012 Nov; 53(11):1764-71. PubMed ID: 23055533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors.
    Zhu H; Zhang L; Dong F; Guo W; Wu S; Teraishi F; Davis JJ; Chiao PJ; Fang B
    Oncogene; 2005 Jul; 24(31):4993-9. PubMed ID: 15824729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts.
    Nawrocki ST; Sweeney-Gotsch B; Takamori R; McConkey DJ
    Mol Cancer Ther; 2004 Jan; 3(1):59-70. PubMed ID: 14749476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis.
    Bazzaro M; Lee MK; Zoso A; Stirling WL; Santillan A; Shih IeM; Roden RB
    Cancer Res; 2006 Apr; 66(7):3754-63. PubMed ID: 16585202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB.
    Russo SM; Tepper JE; Baldwin AS; Liu R; Adams J; Elliott P; Cusack JC
    Int J Radiat Oncol Biol Phys; 2001 May; 50(1):183-93. PubMed ID: 11316563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-kappaB and activator protein-1 related mechanisms.
    Chen Z; Ricker JL; Malhotra PS; Nottingham L; Bagain L; Lee TL; Yeh NT; Van Waes C
    Mol Cancer Ther; 2008 Jul; 7(7):1949-60. PubMed ID: 18645005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical update: proteasome inhibitors in solid tumors.
    Lenz HJ
    Cancer Treat Rev; 2003 May; 29 Suppl 1():41-8. PubMed ID: 12738242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.